Drug Safety Settlement

  • Most Popular
  • Most Shared

REUTERS SHOWCASE

Bernanke Speaks

Bernanke Speaks

Bernanke touts benefits of easing, no hint of pullback.  Full Article 

Sensex Falls

Sensex Falls

Sensex falls for third day; L&T results spark worries.  Full Article 

Copper Shortage

Copper Shortage

Copper smelter closures put cable makers in tight spot.  Full Article 

Tax Avoidance

Tax Avoidance

Factbox: Apple, Amazon, Google and tax avoidance schemes.  Full Article 

Tracking India Gold

Tracking India Gold

Physical gold market awaits fresh import guidelines.  Full Article 

Earnings Season

Earnings Season

L&T looks overseas to offset weak home market  Full Article | Full Coverage 

Bank Acquisition

Bank Acquisition

Srei Infrastructure to buy Austrian bank unit - paper  Full Article 

Just Dial IPO

Just Dial IPO

Just Dial's 9.4 billion rupee IPO covered 11.6 times  Full Article 

Buy, Sell or Hold?

Buy, Sell or Hold?

Confused while buying stocks? Get buy, sell or hold recommendations from VantageTrade.  Full Coverage 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage 

Cipla plans $512 mln takeover of South Africa's Cipla Medpro

Related Topics

Stocks

   
Track BSE Sectoral Indices

Track Markets: BSE Sectoral Indices

Track and analyse performance of all BSE sectoral indices and other global indices on a single page.   Full Coverage 

MUMBAI | Thu Feb 28, 2013 10:24am IST

MUMBAI (Reuters) - Cipla Ltd (CIPL.NS) on Thursday sweetened its offer by 17 percent to take over South Africa's third-largest drugmaker, Cipla Medpro South Africa Ltd (CMPJ.J), ending the uncertainty of an earlier offer that had been put on hold by the Indian company.

Cipla, India's fifth-largest drugmaker by sales, said it would spend about $512 million, or 10 rand a share, to acquire Cipla Medpro and then delist the South African drugmaker.

The Indian company in November 2012 offered to buy 51 percent of Cipla Medpro at 8.55 rand a share. After Cipla's initial offer, the South African company won a 1.4 billion rand government drug contract, leading analysts to revalue the African firm higher.

"With a 100 percent buy-out plan, Cipla will have good operational synergies in the African market," said Siddhant Khandekar, an analyst at ICICI Direct in Mumbai. "However, it is difficult to predict if the payback would happen quickly."

Cipla Chairman Y. K. Hemied told Reuters earlier this month that the November acquisition had been on hold, but did not give any reason. Cipla is the biggest supplier of drugs to Cipla Medpro.

Shares in Cipla were up 0.8 percent at 367.40 rupees by 0426 GMT while the Mumbai market was up 0.53 percent.

(Reporting by Kaustubh Kulkarni; Editing by Jijo Jacob and Matt Driskill)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.